Overcoming antidepressant treatment resistance: Focus on glutamate

Depression: From Psychopathology to Pharmacotherapy

Volumn 27, Issue , 2010, Pages 89-100

  Murrough, James W ^a   Mathew, Sanjay J ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84856873826     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000319509     Document Type: Chapter

References (41)

1. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M, Rush AJ: What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. Psychiatr Serv 2009;60:1439-1445.
2. Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008;33:2080-2092.
3. Mathew SJ: Treatment-resistant depression: recent developments and future directions. Depress Anxiety 2008;25:989-992.
4. Sanacora G, Zarate CA, Krystal JH, Manji HK: Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 2008;7:426-437.
5. Valentine GW, Sanacora G: Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol 2009;78:431-439.
6. Rajkowska G, Miguel-Hidalgo JJ: Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007;6:219-233.
7. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins K, Murrough J, Charney DS, Mathew SJ: Amino acid neurotransmitter concentrations in anterior cingulate and occipital cortex in symptomatic patients with major depression: relationship to treatment resistance. Biol Psychiatry 2009;65:792-800.
8. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354.
9. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
10. Mathew SJ, Murrough J, aan het Rot M, Collins KA, Reich D, Charney DS: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlledcontinuation trial. IntJNeuro psychopharmacol 2010;13:71-82.
11. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine:support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000;57:270-276.
12. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 2004;161:171-174.
13. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK: An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 2005;57:430-432.
14. Singh J, Zarate CA Jr, Krystal AD: Case report: successful riluzole augmentation therapy in treatmentresistant bipolar depression following the development of rash with lamotrigine. Psychopharmacology (Berl) 2004;173:227-228.
15. Zarate CA, Manji HK: Riluzole in psychiatry: a systematic review of the literature. Expert Opin Drug Metab Toxicol 2008;4:1223-1234.
16. Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 2006;163:153-155.
17. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139-145.
18. Price RB, Nock MT, Charney DS, Mathew SJ: Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66:522-526.
19. O'Connor MK, Knapp R, Husain M, Rummans TA, Petrides G, Smith G, Mueller M, Snyder K, Bernstein H, Rush AJ, Fink M, Kellner C: The influence of age on the response of major depression to electroconvulsive therapy: a CORE Report. Am J Geriatr Psychiatry 2001;9:382-390.
20. Phelps LE, Brutsche N, Moral JR, Luckenbaugh DA, Manji HK, Zarate CA Jr: Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry 2009;65:181-184.
21. Krystal JH, Petrakis IL, Limoncelli D, Webb E, Gueorgueva R, D'Souza DC, Boutros NN, Trevisan L, Charney DS: Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients. Neuropsychopharmacology 2003;28:2020-2028.
22. Petrakis IL, Limoncelli D, Gueorguieva R, Jatlow P, Boutros NN, Trevisan L, Gelernter J, Krystal JH: Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry 2004;161:1776-1782.
23. Schuckit MA: An overview of genetic influences in alcoholism. J Subst Abuse Treat 2009;36:S5-S14.
24. Schumann G, Johann M, Frank J, Preuss U, Dahmen N, Laucht M, Rietschel M, Rujescu D, Lourdusamy A, Clarke TK, Krause K, Dyer A, Depner M, Wellek S, Treutlein J, Szegedi A, Giegling I, Cichon S, Blomeyer D, Heinz A, Heath S, Lathrop M, Wodarz N, Soyka M, Spanagel R, Mann K: Systematic analysis of glutamatergic neurotransmission genes in alcohol dependence and adolescent risky drinking behavior. Arch Gen Psychiatry 2008;65:826-838.
25. Hasler G, Drevets WC, Manji HK, Charney DS: Discovering endophenotypes for major depression. Neuropsychopharmacology 2004;29:1765-1781.
26. Institute of Medicine: Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships. Workshop Summary 2008. Washington, Institute of Medicine, 2008.
27. Ressler KJ, Mayberg HS: Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007;10:1116-1124.
28. Davidson RJ, Irwin W, Anderle MJ, Kalin NH: The neural substrates of affective processing in depressed patients treated with venlafaxine. Am J Psychiatry 2003;160:64-75.
29. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, Silva JA, McGinnis S, Glass TG, Martin CC, Fox PT: Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997;8:1057-1061.
30. Salvadore G, Cornwell BR, Colon-Rosario V, Coppola R, Grillon C, Zarate CA Jr, Manji HK: Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009;65:289-295.
31. Drevets WC, Price JL, Furey ML: Brain structural and functional abnormalities in mood disorders:implications for neurocircuitry models of depression. Brain Struct Funct 2008;213:93-118.
32. Drevets WC, Savitz J, Trimble M: The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 2008;13:663-681.
33. Phillips ML, Drevets WC, Rauch SL, Lane R: Neurobiology of emotion perception. 1. The neural basis of normal emotion perception. Biol Psychiatry 2003;54:504-514.
34. Phillips ML, Drevets WC, Rauch SL, Lane R: Neurobiology of emotion perception. 2. Implications for major psychiatric disorders. Biol Psychiatry 2003;54:515-528.
35. Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM: Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008;65:154-164.
36. Duman RS: Depression: a case of neuronal life and death? Biol Psychiatry 2004;56:140-145.
37. Duman RS, Monteggia LM: A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006;59:1116-1127.
38. Sen S, Duman R, Sanacora G: Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008;64:527-532.
39. Machado-Vieira R, Yuan P, Brutsche N, Diazgranados N, Luckenbaugh D, Manji HK, Zarate CA Jr: Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-d-aspartate antagonist. J Clin Psychiatry 2009;70:1662-1666.
40. Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K: Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 2002;16:1328-1330.
41. Borrell-Pagès M, Canals JM, Cordelières FP, Parker JA, Pineda JR, Grange G, Bryson EA, Guillermier M, Hirsch E, Hantraye P, Cheetham ME, Néri C, Alberch J, Brouillet E, Saudou F, Humbert S: Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424.